Negative / Null Result ReportOpen accessMedicine· cited by 23

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

Francesca Faustini; Nicky Dunn; Nastya Kharlamova; Malin Ryner; Annette Bruchfeld; Vivianne Malmström; Anna Fogdell‐Hahn; Iva Gunnarsson · 2021 · Arthritis Research & Therapy

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

BACKGROUND: Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-label therapy for systemic lupus erythematosus (SLE), but data on occurrence and predisposing factors to ADAs in these diseases is limited. OBJECTIVES: To elucidate the rate of occurrence, and risk factors for ADAs against rituximab in SLE and AAV. METHODS: ADAs were detected using a bridging electrochemilumi

Abstract by Francesca Faustini; Nicky Dunn; Nastya Kharlamova; Malin Ryner; Annette Bruchfeld; Vivianne Malmström; Anna Fogdell‐Hahn; Iva Gunnarsson, Arthritis Research & Therapy (2021) — licensed CC BY 4.0.

Read the full paper (open access)